DE602004031455D1 - Regulierung der nahrungspräferenz mit glp-1-agonisten - Google Patents

Regulierung der nahrungspräferenz mit glp-1-agonisten

Info

Publication number
DE602004031455D1
DE602004031455D1 DE602004031455T DE602004031455T DE602004031455D1 DE 602004031455 D1 DE602004031455 D1 DE 602004031455D1 DE 602004031455 T DE602004031455 T DE 602004031455T DE 602004031455 T DE602004031455 T DE 602004031455T DE 602004031455 D1 DE602004031455 D1 DE 602004031455D1
Authority
DE
Germany
Prior art keywords
glp
agonists
regulation
food preference
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004031455T
Other languages
English (en)
Inventor
Kirsten Raun
Voss Pia Von
Liselotte Bjerre Knudsen
Kjell Malmloef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of DE602004031455D1 publication Critical patent/DE602004031455D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Confectionery (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Peptides Or Proteins (AREA)
DE602004031455T 2003-12-09 2004-12-09 Regulierung der nahrungspräferenz mit glp-1-agonisten Active DE602004031455D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301816 2003-12-09
PCT/DK2004/000853 WO2005056036A2 (en) 2003-12-09 2004-12-09 Regulation of food preference using glp-1 agonists

Publications (1)

Publication Number Publication Date
DE602004031455D1 true DE602004031455D1 (de) 2011-03-31

Family

ID=34673547

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004031455T Active DE602004031455D1 (de) 2003-12-09 2004-12-09 Regulierung der nahrungspräferenz mit glp-1-agonisten

Country Status (6)

Country Link
US (2) US20070082844A1 (de)
EP (2) EP1694356B1 (de)
JP (1) JP4865565B2 (de)
AT (1) ATE498404T1 (de)
DE (1) DE602004031455D1 (de)
WO (1) WO2005056036A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143835A1 (en) * 2007-05-15 2008-11-27 Yale University Ghrelin protects substantia nigra dopamine neurons
RS60316B1 (sr) * 2014-05-07 2020-07-31 Novo Nordisk As Lečenje dijabetesa tipa 1 korišćenjem glp-1 i anti-il-21

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU409983B2 (en) 1965-07-19 1970-12-31 Imperial Chemical Industries Of Australia New Zealand Limited Process for the manufacture of thia zolidines and thiazolidines produced thereby
JP2583257B2 (ja) 1986-05-05 1997-02-19 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン向性ホルモン
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
GB8809115D0 (en) 1988-04-18 1988-05-18 Turner R C Syringes
EP0464022B1 (de) 1989-03-20 2000-05-31 The General Hospital Corporation Insulinotropes hormon
JP3262329B2 (ja) 1990-01-24 2002-03-04 アイ． バックレイ，ダグラス 糖尿病治療に有用なｇｌｐ―１アナログ
US5412229A (en) * 1990-08-31 1995-05-02 Sumitomo Electric Industries, Ltd. Semiconductor light detecting device making use of a photodiode chip
SK60893A3 (en) 1990-12-13 1993-10-06 Upjohn Co Fusion polypeptides
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5418218A (en) 1992-07-10 1995-05-23 The University Of Maryland At Baltimore Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent
US5380872A (en) 1992-07-14 1995-01-10 Glaxo Inc. Modulators of cholecystokinin
JP3502651B2 (ja) 1993-02-08 2004-03-02 トリクイント セミコンダクター テキサス、エルピー 電極形成法
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69626660T2 (de) 1995-09-08 2003-08-21 Novo Nordisk As 2-alkylpyrrolidine
EP0876379A1 (de) 1996-01-17 1998-11-11 Novo Nordisk A/S Kondensierte 1,2,4-thiadiazin- und 1,4-thiazinderivate, deren herstellung und verwendung
ATE505485T1 (de) 1996-03-01 2011-04-15 Novo Nordisk As Appetithemmendes peptid, zusammensetzung und verwendung
US5912229A (en) 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
KR100600457B1 (ko) 1996-06-05 2006-07-13 로셰 디아그노스틱스 게엠베하 엑센딘 유사체, 이의 제조방법 및 이를 함유한 약제
JP2000514041A (ja) 1996-07-26 2000-10-24 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物
CA2468374C (en) 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU4863797A (en) 1996-11-12 1998-06-03 Novo Nordisk A/S Use of glp-1 peptides
IL127296A (en) 1996-12-31 2003-01-12 Reddy Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
DK1629849T4 (en) * 1997-01-07 2017-12-04 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exedins and agonists thereof
WO1998043658A1 (en) 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
WO1997041119A1 (en) 1997-05-02 1997-11-06 Dr. Reddy's Research Foundation Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU749271B2 (en) 1997-07-01 2002-06-20 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
IL133604A0 (en) 1997-07-16 2001-04-30 Novo Nordisk As Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
US5957896A (en) 1997-08-11 1999-09-28 Becton, Dickinson And Company Medication delivery pen
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
ATE212991T1 (de) 1997-12-02 2002-02-15 Reddy Research Foundation Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
IL135255A0 (en) 1998-01-30 2001-05-20 Novo Nordisk As An injection syringe
DE69942307D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
EP1056774A1 (de) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminal verkürzte glp-1 derivate
EP1056775B1 (de) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivate von glp-1 und exendin mit verlängertem wirkdauer-profil
EP1060191B1 (de) * 1998-02-27 2010-04-28 Novo Nordisk A/S Abkömmlinge von glp-1 analogen
DE69916811T2 (de) 1998-02-27 2005-04-14 Novo Nordisk A/S Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
EP1306091A3 (de) 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation der Beta-Zellen Vermehrung
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1123279A1 (de) 1998-10-21 2001-08-16 Novo Nordisk A/S Verbindungen, ihre herstellung und verwendung
JP2002527516A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、それらの製造及び使用
US6353018B1 (en) 1998-10-21 2002-03-05 Novo Nordisk A/S Compounds, their preparation and use
WO2000023416A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
JP2002527503A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
US6420137B1 (en) 1998-11-25 2002-07-16 American Home Products Corporation Nucleic acid encoding human neurotensin subtype 2 receptor
PL348237A1 (en) 1998-12-18 2002-05-20 Novo Nordisk As Fused 1,2,4-thiadiazine derivatives, their preparation and use
WO2000041121A1 (en) 1999-01-07 2000-07-13 Ccrewards.Com Method and arrangement for issuance and management of digital coupons and sales offers
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
JP2002534511A (ja) 1999-01-18 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 置換型イミダゾール、それらの調製及び使用
AU2953699A (en) 1999-04-16 2000-11-02 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
WO2000063193A1 (en) 1999-04-16 2000-10-26 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
EE200100529A (et) 1999-04-16 2002-12-16 Dr. Reddy's Research Foundation Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
AU3957900A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
JP2002542246A (ja) 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造及び使用
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
EP1171414A1 (de) 1999-04-20 2002-01-16 Novo Nordisk A/S Verbindungen, ihre herstellung und ihre anwendung
AU3957600A (en) 1999-04-26 2000-11-10 Boehringer Ingelheim International Gmbh Piperidyl-imidazole derivatives, their preparations and therapeutic uses
EP1076066A1 (de) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptide zur Senkung des Blutglukosespiegels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
WO2001057084A1 (en) 2000-01-31 2001-08-09 Novo Nordisk A/S Crystallisation of a glp-1 analogue
AU2001228325A1 (en) 2000-02-01 2001-08-14 Novo-Nordisk A/S Use of compounds for the regulation of food intake
US20030040469A1 (en) * 2000-03-08 2003-02-27 Knudsen Liselotte Bjerre Lowering serum lipids
GB0007071D0 (en) 2000-03-24 2000-05-17 Sams Bernard One-way clutch mechanisms and injector devices
US6399089B1 (en) 2000-05-15 2002-06-04 A. Glenn Braswell Compositions and methods for regulating metabolism and balancing body weight
SI1695983T1 (sl) 2000-06-16 2009-08-31 Lilly Co Eli Analogi glukagonu podobnega peptida-1
ES2243547T3 (es) 2000-07-20 2005-12-01 F. Hoffmann-La Roche Ag Bencenacetamida sustituida para alfa-acilo y alfa heteroatomos como activador de glucokinasa.
AU2002226897B2 (en) 2000-12-07 2007-10-25 Eli Lilly And Company GLP-1 fusion proteins
EP1347982B1 (de) * 2000-12-12 2005-11-16 Neurogen Corporation Spiro[isobenzofuran-1,4'-piperidin]-3-one und 3h-spiroisobenzofuran-1,4'-piperidine
US20020187926A1 (en) 2001-03-07 2002-12-12 Knudsen Liselotte Bjerre Combined use of derivatives of GLP-1 analogs and PPAR ligands
ES2298378T3 (es) 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
WO2003059378A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
AR038102A1 (es) 2002-01-08 2004-12-29 Lilly Co Eli Analogos extendidos de peptido 1 de tipo glucagon
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
EP1575490A4 (de) 2002-06-04 2007-08-08 Lilly Co Eli Modifizierte glucagon-artige peptid-1-analoga
DE10229138B4 (de) 2002-06-28 2008-01-31 Tecpharma Licensing Ag Produktausschüttvorrichtung mit Kolbenstangen-Eilrücksetzung
AU2003283216A1 (en) 2002-12-03 2004-06-23 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
EP1684793B1 (de) * 2003-11-13 2011-09-21 Novo Nordisk A/S Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)-insulin, und eine oberflächenaktive verbindung

Also Published As

Publication number Publication date
JP4865565B2 (ja) 2012-02-01
EP1694356B1 (de) 2011-02-16
ATE498404T1 (de) 2011-03-15
US20100222277A1 (en) 2010-09-02
WO2005056036A2 (en) 2005-06-23
EP2298337A2 (de) 2011-03-23
US20070082844A1 (en) 2007-04-12
EP2298337B1 (de) 2017-02-22
WO2005056036A3 (en) 2005-09-09
EP2298337A3 (de) 2011-06-01
US9486504B2 (en) 2016-11-08
JP2008504217A (ja) 2008-02-14
EP1694356A2 (de) 2006-08-30

Similar Documents

Publication Publication Date Title
WO2007041470A3 (en) High-protein soy-wheat crisps
TW200703718A (en) Luminescence-conversion LED
WO2007106653A3 (en) Led with integral thermal via
DE502007004241D1 (de) Mehrkomponentenkartusche
TW200745522A (en) Light sensor with integrated temperature sensor functionality
ATE386641T1 (de) Ventil, tintenpatrone mit diesem ventil und tintenversorgungsverfahren
TW200731562A (en) Light source comprising LED arranged in recess
WO2006002607A3 (de) Leuchtdiodenanordnung, optisches aufzeichnungsgerät, und verfahren zum gepulsten betreiben wenigstens einer leuchtdiode
ATE427765T1 (de) Infusionsset mit niedrigem profil
TW200711099A (en) Module with radiation-emitting semiconductor-bodies
DE60329303D1 (de) Vakuumzufuhrventilanordnung mit mehrfachregler
WO2009022321A3 (en) Thin backlight using low profile side emitting led
TW200644296A (en) Light source with glass housing
DE602005003470D1 (de) Hochleistungsfähige, mit alkyliertem 4,4'-methylendianilin gehärtete polyurethane auf basis von paraphenylendiisocyanat
HK1091035A1 (en) Battery device
GT200300061S (es) Maletin.
GT200300030S (es) Botella.
EP1846264A4 (de) Led-geformter lichtleiter
ATE299825T1 (de) Selbstkletterndes fahrwerk für fassaden insbesondere glasfassaden
TR200700266T1 (tr) Bir soğutucu.
BR0316160B1 (pt) inserto para direcionamento de fluxo, e, reator provido de pelo menos uma cÂmara do reator contendo o mesmo.
ATE498404T1 (de) Regulierung der nahrungspräferenz mit glp-1- agonisten
DE602006005190D1 (de) Beleuchtungsvorrichtung mit reduziertem Platzbedarf
TW200722861A (en) Backlight module
EP2312599A3 (de) Beleuchtete Tastaturbaugruppe